Obesity and body weight control

March 8, 2018

Amino acid-based therapy for body weight control, energy homeostasis and TIIDM: L-Arginine, a non-essential amino acid that aids in blood flow and in maintaining optimal nitric oxide levels, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 8/March/2018, 6.36 am

Amino acid-based therapy for body weight control, energy homeostasis and TIIDM: L-Arginine, a non-essential amino acid that aids in blood flow and in maintaining optimal nitric oxide levels, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 8/March/2018, 6.36 am https://genomediscovery.org/wp-content/uploads/2018/03/Arginine-may-promote-weight-loss-and-prevent-metabolic-disease-through-up-regulation-of-circadian-clock-protein-REV-ERB.jpg2_.jpg3_.jpg4_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/03/Arginine-may-promote-weight-loss-and-prevent-metabolic-disease-through-up-regulation-of-circadian-clock-protein-REV-ERB.jpg2_.jpg3_.jpg4_.jpg March 8, 2018 March 8, 2018

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

February 14, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: 17-α-Ethinylestradiol (EE), a birth control pill, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 14/February/2018, 10.54 pm

Molecular therapy for body weight control, energy homeostasis and TIIDM: 17-α-Ethinylestradiol (EE), a birth control pill, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 14/February/2018, 10.54 pm https://genomediscovery.org/wp-content/uploads/2018/02/1-1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/1-1.jpg February 14, 2018 February 14, 2018

February 14, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: Hydralazine[Trade name: Apresoline], an anti-hypertensive drug, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 14/February/2018, 7.07 am

Molecular therapy for body weight control, energy homeostasis and TIIDM: Hydralazine[Trade name: Apresoline], an anti-hypertensive drug, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 14/February/2018, 7.07 am https://genomediscovery.org/wp-content/uploads/2018/02/Hydralazine-may-promote-weight-loss-and-prevent-metabolic-disease-through-up-regulation-of-circadian-clock-protein-REV-ERB.jpg2_.jpg3_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/Hydralazine-may-promote-weight-loss-and-prevent-metabolic-disease-through-up-regulation-of-circadian-clock-protein-REV-ERB.jpg2_.jpg3_.jpg February 14, 2018 February 14, 2018

February 8, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing 17α-Estradiol and Aspirin inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 8/February/2018, 11.03 pm

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing 17α-Estradiol and Aspirin inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 8/February/2018, 11.03 pm https://genomediscovery.org/wp-content/uploads/2018/02/1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/1.jpg February 8, 2018 February 8, 2018

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.”…

February 6, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: D-β-Hydroxybutyrate (D-βHB) increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 6/February/2018, 6.58 am

Molecular therapy for body weight control, energy homeostasis and TIIDM: D-β-Hydroxybutyrate (D-βHB) increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 6/February/2018, 6.58 am https://genomediscovery.org/wp-content/uploads/2018/02/D-1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/D-1.jpg February 6, 2018 February 6, 2018

February 4, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pyridoxamine and Triiodothyronine (T3) (PT3) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 4/February/2018, 9.30 am

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pyridoxamine and Triiodothyronine (T3) (PT3) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 4/February/2018, 9.30 am https://genomediscovery.org/wp-content/uploads/2018/02/Pyridoxamine-and-Triiodothyronine-T3-inhibits-DNMT3a-expression-induces-FGF21-expression-and-cardiac-ageing1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/Pyridoxamine-and-Triiodothyronine-T3-inhibits-DNMT3a-expression-induces-FGF21-expression-and-cardiac-ageing1.jpg February 4, 2018 February 4, 2018

Popular Post